There are a few caveats before translating these results into clinical practice; firstly, these patients did not receive trastuzumab; the study was initiated before the studies of adjuvant trastuzumab were mature and adjuvant trastuzumab became standard practice for patients whose tumours expressed HER-2; however, only 5% of patients had HER2 over-expressed tumours in this study. The gene discussed is ERBB2; the disease is neoplasm.